AUTL · Autolus Therapeutics plc · Webcasts, Transcripts & Audio
$1.14
-0.03 (-2.56%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q1 2026 earnings call transcript
Market Cap
$303.43M
Shares
266.16M
Volume · Nov 16
2.35M
Avg daily vol (3M)
2.13M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Autolus Therapeutics plc Webcasts
Earnings calls, investor updates, investor days and conferences for Autolus Therapeutics plc (AUTL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-17
Autolus Therapeutics plc (AUTL) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-10
Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call
Revenue
$41.24M
▲ 94.6% YoY Diluted EPS
$-0.21
Gross margin
56.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-11
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call
Revenue
$45.69M
▲ 118.4% YoY Diluted EPS
$-0.15
Gross margin
55.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-30
Autolus Therapeutics plc (AUTL) June 30, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-30
Autolus Therapeutics plc (AUTL) June 30, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Autolus Therapeutics plc (AUTL) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Autolus Therapeutics plc (AUTL) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-02
Autolus Therapeutics plc (AUTL) June 2, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-02
Autolus Therapeutics plc (AUTL) June 2, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-14
Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript
Confident tone
Commercial launch of Ocastle
Gross margin improvement
Revenue and full-year guidance
Revenue
$26.22M
▲ 191.9% YoY Diluted EPS
$-0.27
Gross margin
6.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Investor Update
Investor event
2026-04-08
Autolus Therapeutics plc (AUTL) April 8, 2026 Investor Update Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Investor Update
Investor event
2026-04-08
Autolus Therapeutics plc (AUTL) April 8, 2026 Investor Update Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-27
Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript
Confident tone
Pipeline expansion (OB-Cell, Catalyst, Carlyle, Lumina)
Safety/efficacy in real-world setting
ROCCA real-world data consortium
Revenue
$24.29M*
▲ 83655.2% YoY Gross margin
-4.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript
Confident tone
Obe-cel U.S. Commercial Launch
Market Share Growth in ALL
Pipeline Expansion
Revenue
$21.19M
Diluted EPS
$-0.30
Gross margin
-35.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript
Positive tone
Obe-cel US commercial launch
Obe-cel regulatory and EU/UK market access
Pipeline expansion (pediatric ALL, autoimmune)
Revenue
$20.92M
Diluted EPS
$-0.18
Gross margin
-16.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript
Confident tone
Commercial launch of AUCATZYL
Pipeline expansion into lupus and other indications
Manufacturing and dosing variability risk
Revenue
$8.98M
▼ 11% YoY Diluted EPS
$-0.26
Gross margin
-99.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Call Transcript
Confident tone
AUCATZYL U.S. commercial launch
CARLYSLE autoimmune study
Center onboarding and patient access expansion
Revenue
$29,000*
Gross margin
-39165.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript
Confident tone
AUCATZYL FDA approval and launch readiness
Pipeline data presentations at ASH
SLE and pediatric pipeline expansion
Revenue
$0
Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call
Revenue
$0
Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-17
Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript
Confident tone
Obe-cel regulatory progress and PDUFA
Pipeline expansion into autoimmune (SLE)
FELIX study results and persistence/disease burden
Revenue
$10.09M
Diluted EPS
$-0.24
Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript
Confident tone
FELIX study clinical data
Pipeline expansion into autoimmune
obe-cel BLA review and regulatory progress
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–21 of 21 webcasts
Key facts
CIK
1730463
CUSIP
05280R100
13F (30d)
86 filings
71 filers
Visit website
Investor relations